#AstraZeneca (-15.04% in London) shares sink on MYSTIC study results.
https://t.co/6WhRGOWaN3
$AZN #pharma #stocks https://t.co/KngaxpNgoJ
Kan inte bli fel av @dagensindustri om man kör en buffé av rubriker. #astrazeneca #azn $AZN https://t.co/XUojNQAEXl
RT @bio_clouseau: $TSRO Takeda partner PARP in japan. 100 M u/f $CLVS $AZN $BGNELooking less likely anyone will buy company 4 a PARP?? http…
$AZN CEO SAYS NOTHING FURTHER TO ADD FOLLOWING RUMOURS HE MIGHT BE LEAVING TO JOIN $TEVA
NOT COMMENTING BUT PROUD TO BE CEO $AZN
$AZN Acalabrutinib BTK submission now 2H17 from 2Q17. Bydureon appears to failed efficacy endpt, manufacturing issues with 2.7B drug ZS9
Immunotherapy setback for AstraZeneca https://t.co/zGnLENYys1 $AZN
Immunotherapy setback for AstraZeneca https://t.co/3CQsLGtwMV $AZN
RT @iankmsmith: AstraZeneca $AZN down 16% today after major setback to Mystic trial for lung cancer treatment https://t.co/zCeyPlmwPo
RT @ByAmyBrown: $AZN's Soriot tells press he is "committed" to the job. Mystic fail probably not the distraction he was hoping for today..…
RT @bio_clouseau: $TSRO Takeda partner PARP in japan. 100 M u/f $CLVS $AZN $BGNELooking less likely anyone will buy company 4 a PARP?? http…
RT @ETXCapital: Big moves on the #FTSE this morning
$AZN -15% on lung cancer drug failure
$AAL +4% on early resumption of dividends https:…
$AZN's Soriot insists OS read out in Mystic still most important - "where we placed most statistical power"
Interim dividend unchanged in HY results today. Liberum says $AZN worth £49/share ex-Mystic, but with some other success. It's at £43
H1 2017 results show momentum in Emerging Markets, with China continuing to perform well $AZN https://t.co/Yi5ZMrKhAJ
RT @JacobPlieth: @helentbbc @deniseroland It's clearly terrible news, but at this point I don't think Mystic is (totally) dead. Awaiting a…
RT @ByAmyBrown: $AZN's Soriot tells press he is "committed" to the job. Mystic fail probably not the distraction he was hoping for today..…
AstraZeneca's Pascal Soriot opens media call, says won't comment on speculation he's leaving, but says "committed", "proud to be CEO" $AZN
RT @JacobPlieth: @helentbbc @deniseroland It's clearly terrible news, but at this point I don't think Mystic is (totally) dead. Awaiting a…
$AZN's Soriot tells press he is "committed" to the job. Mystic fail probably not the distraction he was hoping for today.. $TEVA
@biotechinvstr Maybe $AZN thinks PARP current value based on $TSRO $CLVS is just paper value and actual value is le… https://t.co/4FtaIScNwF
AstraZeneca plc's hold rating reiterated at Shore Capital. https://t.co/ug2xwBdUNd $AZN #AZN
Soriot won't comment on Teva rumors but says he's committed to $AZN's strategy of returning to growth.
@helentbbc @deniseroland It's clearly terrible news, but at this point I don't think Mystic is (totally) dead. Awa… https://t.co/oKq8tdnNvK
We announced our H1 2017 results today - our Growth Platforms demonstrated overall growth of 3% $AZN https://t.co/21sTwL0OVh
That's one of four announcements on the RNS so far today for $AZN, including oncology deal with Merck. It's in surv… https://t.co/aLgnfHYlE6
AstraZeneca $AZN down 16% today after major setback to Mystic trial for lung cancer treatment https://t.co/zCeyPlmwPo
RT @AstraZeneca: Overall performance in H1 2017 was in line with expectations. Financial guidance for 2017 reiterated $AZN https://t.co/Fh9…
@deniseroland It's a "Thank Fuck We Didn't Own It" situation $PFE $AZN @helentbbc
$TSRO Takeda partner PARP in japan. 100 M u/f $CLVS $AZN $BGNELooking less likely anyone will buy company 4 a PARP?? https://t.co/2o58HozAUH
RT @AstraZeneca: Overall performance in H1 2017 was in line with expectations. Financial guidance for 2017 reiterated $AZN https://t.co/Fh9…
Come back, Ian... All is forgiven!! Spin that coin, please $PFE $AZN https://t.co/6NlJwDFlX8
Overall performance in H1 2017 was in line with expectations. Financial guidance for 2017 reiterated $AZN https://t.co/Fh9LAgdrdX
RT @JohnCendpts: $AZN -15%, wiping out $12B-plus in market cap on MYSTIC #fail
https://t.co/RopgTQ68k5
@JacobPlieth @Asthika $AZN diagnostic cutoff 25% thus naturally stratified by 25% but didn't have foresight to stra… https://t.co/8yM2M2giF5
$AZN holding music a combo of soft, bitter-sweet jazz, and upbeat funk...
#AstraZeneca $AZN @AstraZeneca has fallen 16% in opening trading today following lung cancer drug trial failure… https://t.co/1pTYRWlYs0
What are the chances that pseudoprogression has confounded MYSTIC PFS data? Any other theoretical +ves? Thanks for any thoughts $AZN
RT @conkers3: @Antony_SW11 @marben100 @mattbird55 @DianaEPatterson @Financial_Orbit @AstraZeneca @JohnCendpts @jimmhk @asibiza1 @TheIdleInv…
RT @namithaj: Mystic troubles at AstraZeneca, record slump in shares $AZN https://t.co/S3o2rkTwOt via @business https://t.co/TS5tSEgGq8
RT @biotechinvstr: JPM now with similar tone, and also questions the decision to partner and dilute Lynparza, which removes upside from a l…
RT @biotechinvstr: MS the first note out I see, highlighting their 20% downside scenario $AZN https://t.co/1tdus6bZGT
RT @biotechinvstr: I pulled together some sellside previews on the PFS outcome for $AZN (GS Leerink MS and JPM). Point to stock down ~20%…
RT @bradloncar: Here we go finally... $AZN PR announcing that MYSTIC did not succeed on PFS. https://t.co/bFZmOqvom3
One point from today is that $AZN did, after all, go for 25% PD-L1 cut. Luck (well, relatively speaking)? Foresight… https://t.co/vTvCJKJkAI
RT @namithaj: Mystic troubles at AstraZeneca, record slump in shares $AZN https://t.co/S3o2rkTwOt via @business https://t.co/TS5tSEgGq8
$AZN Reports initial results from MYSTIC lung trial; combination of Imfinzi and tremelimumab did not meet the primary endpoint
Astrazeneca Q2 Core EPS $ 0.87 v $0.80e, Rev $5.05B v $5.00Be
- Affirms FY17 $AZN
RT @JacobPlieth: Retweeting this for the benefit of those trying to unravel today's MYSTIC fail $AZN https://t.co/nirtgOBE4n
RT @namithaj: Mystic troubles at AstraZeneca, record slump in shares $AZN https://t.co/S3o2rkTwOt via @business https://t.co/TS5tSEgGq8
RT @JacobPlieth: Retweeting this for the benefit of those trying to unravel today's MYSTIC fail $AZN https://t.co/nirtgOBE4n
RT markets "RT namithaj: Mystic troubles at AstraZeneca, record slump in shares $AZN https://t.co/RlQniKJdWJ via … https://t.co/IRS2NJfA4E"
RT namithaj: Mystic troubles at AstraZeneca, record slump in shares $AZN https://t.co/CfF1p7evJV via business https://t.co/UcwX9MdiwD
Retweeting this for the benefit of those trying to unravel today's MYSTIC fail $AZN https://t.co/nirtgOBE4n
RT @namithaj: Mystic troubles at AstraZeneca, record slump in shares $AZN https://t.co/S3o2rkTwOt via @business https://t.co/TS5tSEgGq8
#Media please join the $AZN Q2 2017 Results Call at 09.00 (BST). Dial-in details here: https://t.co/pwLfMUXQRD
If you were part of the research team on that Mystic trial, how tempted would you have been to short $AZN ..?
Mystic troubles at AstraZeneca, record slump in shares $AZN https://t.co/S3o2rkTwOt via @business https://t.co/TS5tSEgGq8
What's the dialling code for Israel? A friend wants to know $AZN
$AZN:
AstraZeneca Shares Plunge the Most in 8 Years After Key Cancer …:
https://t.co/zLNC2aQiXm
The #vssporte $AZN transactions. Now 200 ADRs left, with break-even at $34.93. https://t.co/YTzIbensbC
Överreaktion i $AZN Även om MYSTIC var en viktig studie har fortfarande mkt på gång med en stark rapport. Buy the dip!
@Antony_SW11 @marben100 @mattbird55 @DianaEPatterson @Financial_Orbit @AstraZeneca @JohnCendpts @jimmhk @asibiza1… https://t.co/vn2OziVMWZ
Astra CEO: He should have gone to Teva… https://t.co/TWasezR4Yq via @Wall StreetWires $AZN
Fyller på $AZN idag. Vilka handlar på dessa nivåer?
Köpte calls i $AZN redan innan ryktet om VDs avgång. Och idag efter raset är de värda noll. Förlust 170k
JPM now with similar tone, and also questions the decision to partner and dilute Lynparza, which removes upside fro… https://t.co/jUVRp890s2
Köper $AZN här.. lär återhämta sig under veckorna som kmr.
@Antony_SW11 @marben100 @mattbird55 @DianaEPatterson @Financial_Orbit @AstraZeneca @JohnCendpts @jimmhk @asibiza1… https://t.co/UgLtbfnNvs
RT @JohnCendpts: $AZN -15%, wiping out $12B-plus in market cap on MYSTIC #fail
https://t.co/RopgTQ68k5
$AZN - kul aktie för jämviktstrading. Dagslägsta hittills 464, kirurgiskt på stöd. Panik först om nästa stöd 448 pu… https://t.co/tWDMbroMEP
$AZN -15%, wiping out $12B-plus in market cap on MYSTIC #fail
https://t.co/RopgTQ68k5
RT @odibro: $AZN $MRK Establish Strategic Oncology Collab to Maximize Potential of PARP & MEK Inhibitors in Combo w/PD-L1/PD-1 https://t.c…
RT @BiotechRadar: AstraZenaca $AZN -16% in London after MYSTIC trial fail
RT @SimonKingFW: $AZN down 15% pre-market
$AZN partners with $MRK on development of olaparaib & selumetinib
https://t.co/11mOiricPZ via @FT
RT @odibro: $AZN $MRK Establish Strategic Oncology Collab to Maximize Potential of PARP & MEK Inhibitors in Combo w/PD-L1/PD-1 https://t.c…
Tempted to start buying back, but not quite sure $AZN has bottomed yet.
That order didn't get filled, so I still have those 200 $AZN ADRs representing 100 "AZN ord shares $0.25".
AstraZeneca $AZN announced that MYSTIC lung cancer treatment failed the Phase 3 trial and Shares down 16
Största nedgången i aktien någonsin så vitt vi kan se. $AZN
RT @_BenWright_: And there it goes. AstraZeneca's shares fall 15.5% at the open $AZN
RT @bradloncar: Oh man.... $AZN really snuck this in on one tiny slide. MYSTIC PFS NOT met. Horrible communications. https://t.co/GL1tqzyzgm
RT @JohnCendpts: AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails in first-line lung cancer
$AZN $MRK
https://t.co/Ropg…
$AZN down 15 percent after a next-gen cancer drug fails tests https://t.co/5d438dVgHm
And there it goes. AstraZeneca's shares fall 15.5% at the open $AZN
RT @BiotechRadar: AstraZenaca $AZN -16% in London after MYSTIC trial fail
$AZN down 15% pre-market
AstraZenaca $AZN -16% in London after MYSTIC trial fail
RT @bradloncar: Here we go finally... $AZN PR announcing that MYSTIC did not succeed on PFS. https://t.co/bFZmOqvom3
RT @bradloncar: Oh man.... $AZN really snuck this in on one tiny slide. MYSTIC PFS NOT met. Horrible communications. https://t.co/GL1tqzyzgm
RT @biotechinvstr: MS the first note out I see, highlighting their 20% downside scenario $AZN https://t.co/1tdus6bZGT
RT @ETXCapital: Big moves on the #FTSE this morning
$AZN -15% on lung cancer drug failure
$AAL +4% on early resumption of dividends https:…
It's all over for $AZN #Astrazeneca - what does #Mystic failure mean for $BMY #BristolMyersSquibb ?? #Pharma #Drugs
Big moves on the #FTSE this morning
$AZN -15% on lung cancer drug failure
$AAL +4% on early resumption of dividen… https://t.co/PH8T2rotJT
RT @odibro: $AZN $MRK Establish Strategic Oncology Collab to Maximize Potential of PARP & MEK Inhibitors in Combo w/PD-L1/PD-1 https://t.c…
RT @JohnCendpts: AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails in first-line lung cancer
$AZN $MRK
https://t.co/Ropg…
Big moves on the #FTSE this morning
$AZN -15% on lung cancer drug failure
$AAL +4% on early resumption of dividends https://t.co/0Ael6ylxUq
$AZN $MRK Establish Strategic Oncology Collab to Maximize Potential of PARP & MEK Inhibitors in Combo w/PD-L1/PD-1 https://t.co/idU9xuvkJN
RT @ByAmyBrown: $AZN hits the wires (burying news?) with PR onslaught as Mystic fails at 1st cut - Tagrisso Flaura P3 hit, $MRK onc collab,…
Oof. $AZN down 15.5% at the open.
RT @JohnCendpts: AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails in first-line lung cancer
$AZN $MRK
https://t.co/Ropg…
As Astrazeneca's Mystic fails $AZN offers up $8.5bn oncology collaboration with $MRK as a consolation prize.
@DrSManian $azn $mrk deal should take some of the sting away
RT @JohnCendpts: AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails in first-line lung cancer
$AZN $MRK
https://t.co/Ropg…
AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails in first-line lung cancer
$AZN $MRK
https://t.co/RopgTQ68k5
$AZN $MRK #Oncology collaboration https://t.co/p6N0YWj86Y
$AZN hits the wires (burying news?) with PR onslaught as Mystic fails at 1st cut - Tagrisso Flaura P3 hit, $MRK onc collab, Q2 results.
And strikes a deal with $mrk with parp mek $azn
$AZN Also announcing oncology collaboration with $MRK to jointly develop & commercialize PARP inhibitor Lynparza &… https://t.co/7BKrNVUUaj
RT @slick_trader24: $BMY files suit against Genentech $RHHBY.. separate suits against $AZN $PFE. Already settled with $MRK whom now pays ro…
$BMY $RHHBY $AZN $PFE $MRK Cancer drug war heats up as Big Pharma squares off against Genentech… https://t.co/dXka6MMrPI
$BMY files suit against Genentech $RHHBY.. separate suits against $AZN $PFE. Already settled with $MRK whom now pays royalties to BMS.
Price Returns vs Expected Daily Move $DVAX $BIIB $CELG $GILD $AZN $VRX $BMY $EW $PFE $CVS $MRK $AMGN… https://t.co/9LVfH4qjqK
RT @megtirrell: BMO's Alex Arfaei says there's a good chance $AZN will release MYSTIC top-line results tomorrow with earnings $BMY $MRK
RT @PharmaCentra: #FDA Novel Approvals https://t.co/WKeHM7FDbQ … … $GILD $PBYI $AZN $PFE $AKBLF $SNY $REGN $RHHBY $NVS $TSRO #Pharmaceutica…
7/27 #Watchlist: $AMD $TWTR $ADOM $GILD $EGRX
$BMY $CELG $AZN $ALXN $CLF $TWTR
Watching for next week: $PIXY $AIRG $QTM
#AllStarTradingTeam
RT @biotechinvstr: $AZN MYSTIC fails PFS even with 25% PD-L1 cutoff population. No mention of OS trends in the PR- implies they're not seei…
$AZN at 28.7$ feels overly oversold, likely goes higher towards the confrence call later for clarifications.
RT @jq1234t: $AZN Imfinzi + tremelimumab combo didn't meet primary endpoint of improving PFS vs SoC in PD-L1 >=25% 1st line NSCLC
https://t…
News came as $AZN reported that drug sales fell again in Q2, hit by a loss of patents on blockbusters such as the cholesterol pill Crestor.
RT @JacobPlieth: S Bohen confirms that MYSTIC OS will be out in H1 2018. Also says interim looks before that, but no comment on when $AZN
RT @biotechinvstr: Citi throwing in the towel on MYSTIC OS, reckons NEPTUNE unlikely to be sufficient for approval, expects 20% negative im…
AstraZeneca's second-quarter sales drop 10 percent, weighed down by Crestor, Seroquel XR patent expiries https://t.co/Fp46FC95Zq $AZN
$AZN: “Despite the outcome of the initial readout, we must be patient as the Mystic trial continues as planned to evaluate overall survival”
RT @biotechinvstr: Citi throwing in the towel on MYSTIC OS, reckons NEPTUNE unlikely to be sufficient for approval, expects 20% negative im…
RT @biotechinvstr: Citi throwing in the towel on MYSTIC OS, reckons NEPTUNE unlikely to be sufficient for approval, expects 20% negative im…
RT @bradloncar: Oh man.... $AZN really snuck this in on one tiny slide. MYSTIC PFS NOT met. Horrible communications. https://t.co/GL1tqzyzgm
Citi throwing in the towel on MYSTIC OS, reckons NEPTUNE unlikely to be sufficient for approval, expects 20% negati… https://t.co/7j1n8hnURP
$AZN Imfinzi+tremelimumab combination did not meet a primary endpoint of progression-free survival compared to chemotherapy
S Bohen confirms that MYSTIC OS will be out in H1 2018. Also says interim looks before that, but no comment on when $AZN
Market report: £10bn wiped off AstraZeneca as drug trials flops $AZN, plus Lloys $LLOY, Diageo $DGE and lots more… https://t.co/J9sTGa1CWW
RT @AstraZeneca: H1 2017 is in line with expectations & we remain focused on bringing our strong science to patients $AZN https://t.co/swsS…
RT @AstraZeneca: This morning we reported our H1 2017 Results - our Core EPS was up a little $AZN https://t.co/IxHM0koxif
RT @JohnCendpts: Soriot talks about "enormous progress" -- investors unlikely to agree today
$AZN
https://t.co/RopgTQ68k5
RT @AstraZeneca: H1 2017 in line with expectations & sales from Growth Platforms increased overall. Financial guidance for 2017 reiterated…
Market report: £10bn wiped off AstraZeneca as drug trials flops $AZN, plus Lloys $LLOY, Diageo $DGE and lots more… https://t.co/YNi0BTlXRq
$AZN shares tumble 15% on big drug trial setback https://t.co/r45SgcsXtE https://t.co/Lcnbqh5bZp
$AZN plunge wipes 40pts off FTSE this morning. Index flat as a result
HUGE setback for @AstraZeneca - imfinzi MYSTIC trial fails to met PFS endpoint - $AZN down 15% premarket https://t.co/Kgg8tfez4X
H1 2017 is in line with expectations & we remain focused on bringing our strong science to patients $AZN https://t.co/swsSLKhPv2
RT @AstraZeneca: H1 2017 is in line with expectations & we remain focused on bringing our strong science to patients $AZN https://t.co/qcfe…
RT @conkers3: @Antony_SW11 @marben100 @mattbird55 @DianaEPatterson @Financial_Orbit @AstraZeneca @JohnCendpts @jimmhk @asibiza1 @TheIdleInv…
RT @conkers3: @Antony_SW11 @marben100 @mattbird55 @DianaEPatterson @Financial_Orbit @AstraZeneca @JohnCendpts @jimmhk @asibiza1 @TheIdleInv…
$AZN:
Immunotherapy setback for AstraZeneca:
https://t.co/fpbEK1WHUw
Oh, and Soriot is committed to returning to growth, so don't ask about $TEVA
$AZN
RT @JacobPlieth: What's the dialling code for Israel? A friend wants to know $AZN
Ian Read waking up this morning $PFE $AZN https://t.co/0WaN6QeF4y
RT @JohnCendpts: $AZN -15%, wiping out $12B-plus in market cap on MYSTIC #fail
https://t.co/RopgTQ68k5
Soriot talks about "enormous progress" -- investors unlikely to agree today
$AZN
https://t.co/RopgTQ68k5
This morning we reported our H1 2017 Results - our Core EPS was up a little $AZN https://t.co/IxHM0koxif
RT @iankmsmith: Behind $AZN other biggest All-Share faller is Countrywide $CWD, down 10%, while Foxtons $FOXT down 5%. Another bad day for…
@sciencescanner No one has actually mentioned "pseudoprogression" yet $AZN
Of course its a possibility. But a probability? Surely not. $AZN can spin hard, but its bad news for them https://t.co/mhBs7I2Adn
$AZN ASTRAZENECA CEO SAYS I'M NOT A QUITTER
SAYS OTHER COMPANIES HAVE EXPERIENCED SETBACKS IN #IMMUNO_ONCOLOGY IT IS A VERY VOLATILE FIELD
Buy 60 $AZN ordinary shares (120 ADRs), limit 4300 GBp, in London trading. #vssporte
RT @Borsredaktion: Marknadens dom efter det misslyckade studieresultatet. $AZN https://t.co/Xt8b37Pptq
$AZN's claims as a 1st line #treatment in preference to #chemotherapy, just blew up casting doubt on growth plans. https://t.co/HymO89XSbh
How to deny something without actually denying it: $AZN Soriot's latest comment on Teva rumor: "I'm not a quitter"
Behind $AZN other biggest All-Share faller is Countrywide $CWD, down 10%, while Foxtons $FOXT down 5%. Another bad day for the estate agents
Time to fully close down $AZN and $GSK. They operate like national Co run by bureaucrats. No innovative juices whatsoever. Sad.
RT @JacobPlieth: Soriot & Bohen are dropping heavy hints about possibility to hit OS when PFS fails, citing Keytruda, Opdivo etc $AZN
RT @conkers3: @Antony_SW11 @marben100 @mattbird55 @DianaEPatterson @Financial_Orbit @AstraZeneca @JohnCendpts @jimmhk @asibiza1 @TheIdleInv…
Immunotherapy setback for AstraZeneca $AZN https://t.co/HymO89XSbh
AstraZeneca plc 26.6% Potential Upside Indicated by Liberum Capital - https://t.co/KBUnij0mz0 - $AZN
RT @biotechinvstr: I pulled together some sellside previews on the PFS outcome for $AZN (GS Leerink MS and JPM). Point to stock down ~20%…
Soriot & Bohen are dropping heavy hints about possibility to hit OS when PFS fails, citing Keytruda, Opdivo etc $AZN
RT @SHARESmag: Market report: £10bn wiped off AstraZeneca as drug trials flops $AZN, plus Lloys $LLOY, Diageo $DGE and lots more
https://…
$AZN ASTRAZENECA CEO SAYS DOESN'T SEE AZ AS MORE VULNERABLE TO TAKEOVER AFTER MYSTIC RESULTS
#AstraZeneca Falls 16% as Drug Trial Falters | @AstraZeneca $AZN https://t.co/BysurbwT9U https://t.co/BllXAnZMUG
RT @JacobPlieth: S Bohen confirms that MYSTIC OS will be out in H1 2018. Also says interim looks before that, but no comment on when $AZN
RT @bradloncar: Here we go finally... $AZN PR announcing that MYSTIC did not succeed on PFS. https://t.co/bFZmOqvom3
Soriot: "I'm here today.. very committed to future". Can he stay? "You'll have to ask the board - this is pharma.. you take risk" $AZN
RT @biotechinvstr: Citi throwing in the towel on MYSTIC OS, reckons NEPTUNE unlikely to be sufficient for approval, expects 20% negative im…
Here are this week's top 25 #VPI stocks
$MYL $IBM $GS $DOW $BBY $MMM $AZN $RTN $PYPL $SIRI $MXIM $XLNX $AEO $SBUX
https://t.co/c7sxeQGV0F
Here are this week's top 25 #VPI stocks
$MYL $IBM $GS $DOW $BBY $MMM $AZN $RTN $PYPL $SIRI $MXIM $XLNX $AEO $SBUX
https://t.co/8F5dJcmPrJ
And 55 GBP was pretty the 2016 and the recent high for $AZN shares. https://t.co/rMAlT3UXXK
RT @bradloncar: Oh man.... $AZN really snuck this in on one tiny slide. MYSTIC PFS NOT met. Horrible communications. https://t.co/GL1tqzyzgm
#StockToWatch as AstraZeneca $AZN shares tumble 15% on big drug trial setback. Discover more: https://t.co/2LEGYTmAiX #SmarterTrading
Playing for BIG stakes:
$AZN -15%
$MRK +4%
$BMY -6%
https://t.co/RopgTQ68k5
RT @SHARESmag: Market report: £10bn wiped off AstraZeneca as drug trials flops $AZN, plus Lloys $LLOY, Diageo $DGE and lots more
https://…
See https://t.co/WNy9bPcOqT and https://t.co/aXalJ4BMIR. $PFE $AZN
Interesting that the $PFE acquisition of $AZN, that didn't quite happen in 2014, was rumoured to be at around 55 GBP for AZN ord shares.
@FierceBiotech Could not meet even PFS low bar ... sad, really sad $AZN
@bradloncar @JacobPlieth Kepler: $AZN Previous PD-(L)1s including Roche’s Tecentriq and
Merck & Co’s Keytruda hav… https://t.co/6spOYJ8x6w
$AZN
Immunotherapy setback for AstraZeneca
$AZN - AstraZeneca H1 2017 Results
https://t.co/NSDoM2e4eJ https://t.co/OtjndPBfXf
RT @biotechinvstr: JPM now with similar tone, and also questions the decision to partner and dilute Lynparza, which removes upside from a l…
RT @JacobPlieth: S Bohen confirms that MYSTIC OS will be out in H1 2018. Also says interim looks before that, but no comment on when $AZN
RT @biotechinvstr: Citi throwing in the towel on MYSTIC OS, reckons NEPTUNE unlikely to be sufficient for approval, expects 20% negative im…
@JacobPlieth @bradloncar Why is $AZN giving up PARP combo upside by partnering with MRK versus showing confidence i… https://t.co/JZwfdVCKP8
$13 billion market cap loss; $AZN in bullets https://t.co/Pm5jeMCHkJ
@bradloncar @JacobPlieth DB: $AZN trial will continue until final OS data avail18
remains perfectly feasible that O… https://t.co/rRIjCMFX31
RT @fwpharma: UPDATE: AstraZeneca's shares plunge 15% on failure of Imfinzi, tremelimumab in key lung cancer study https://t.co/leX9crIobs…
Good morning! (Not for $AZN, with MYSTIC...) https://t.co/Ulc5bQoSpN
UPDATE: AstraZeneca's shares plunge 15% on failure of Imfinzi, tremelimumab in key lung cancer study https://t.co/leX9crIobs $AZN
RT @SHARESmag: Market report: £10bn wiped off AstraZeneca as drug trials flops $AZN, plus Lloys $LLOY, Diageo $DGE and lots more
https://…
'I'm not a quitter'= 'I prefer taking home millions each year w/out adding value to the company. Not a bad deal.'… https://t.co/a6C7aNmbmu
RT @reutersBenHir: #AstraZeneca CEO #Soriot still not saying if he might go to #Teva - 'only thing I tell you is I'm here today' and 'proud…
RT @AstraZeneca: H1 2017 is in line with expectations & we remain focused on bringing our strong science to patients $AZN https://t.co/swsS…
$AZN #CRESTOR (adults high triglycerides) sales drooped 43% (YOY-H1) duo TO #generic competition $TEVA $MYL .lost revs of more than 900M$
@bradloncar It's a long shot, but clearly still possible for $AZN to hit OS (on one of the cuts of the data anyway)
RT @AstraZeneca: H1 2017 is in line with expectations & we remain focused on bringing our strong science to patients $AZN https://t.co/swsS…
S Bohen: we have enabled narrower cuts of PD-L1 expression than 25% in MYSTIC, but aren't revealing detail yet $AZN
RT @JacobPlieth: S Bohen: we haven't had time to dig deep into MYSTIC data yet, but pseudoprogression is unlikely to have been confounding…
S Bohen: we haven't had time to dig deep into MYSTIC data yet, but pseudoprogression is unlikely to have been confounding factor $AZN
RT @bradloncar: Oh man.... $AZN really snuck this in on one tiny slide. MYSTIC PFS NOT met. Horrible communications. https://t.co/GL1tqzyzgm
$AZN #Seroquel (dementia psychosis) sales drooped 62% (YOY-H1) duo TO #generic competition $TEVA $MYL $ENDO #LUPIN $IPCI .lost revs of 263M$
#AstraZeneca CEO #Soriot still not saying if he might go to #Teva - 'only thing I tell you is I'm here today' and 'proud to lead AZ' $AZN
Immunotherapy setback for AstraZeneca https://t.co/AUhTTp1yRq $AZN
RT @JohnCendpts: AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails in first-line lung cancer
$AZN $MRK
https://t.co/Ropg…
@jq1234t @biotechinvstr @bradloncar Sad fact: many $AZN investors are fixated on dividend and little else
@biotechinvstr @JacobPlieth @bradloncar Just $AZN continuation of externalisation revenue path by trading future gr… https://t.co/tXlarI5aMJ
RT @portefeuillefun: Interesting that the $PFE acquisition of $AZN, that didn't quite happen in 2014, was rumoured to be at around 55 GBP f…
Några long only som tankar $AZN idag?
RT @JacobPlieth: Ian Read waking up this morning $PFE $AZN https://t.co/0WaN6QeF4y
RT @bradloncar: Oh man.... $AZN really snuck this in on one tiny slide. MYSTIC PFS NOT met. Horrible communications. https://t.co/GL1tqzyzgm
RT @fwpharma: UPDATE: AstraZeneca's shares plunge 15% on failure of Imfinzi, tremelimumab in key lung cancer study https://t.co/leX9crIobs…
RT @JacobPlieth: Soriot & Bohen are dropping heavy hints about possibility to hit OS when PFS fails, citing Keytruda, Opdivo etc $AZN
RT @adamfeuerstein: Good morning! (Not for $AZN, with MYSTIC...) https://t.co/Ulc5bQoSpN
RT @JohnCendpts: Playing for BIG stakes:
$AZN -15%
$MRK +4%
$BMY -6%
https://t.co/RopgTQ68k5
RT @JacobPlieth: Soriot & Bohen are dropping heavy hints about possibility to hit OS when PFS fails, citing Keytruda, Opdivo etc $AZN
$AZN: AstraZeneca and Merck (MRK) form strategic oncology collaboration https://t.co/XQtLBWIBhh
RT @JacobPlieth: Ian Read waking up this morning $PFE $AZN https://t.co/0WaN6QeF4y
In short, it's still unclear whether rejecting the 2014 takeover offer was a mistake. Everyone hate $AZN, but the stock has done just fine.
RT @JohnCendpts: Playing for BIG stakes:
$AZN -15%
$MRK +4%
$BMY -6%
https://t.co/RopgTQ68k5
RT @Miljenkoz: @bradloncar So, did MI6 threaten Pascal not to leave for Teva? $AZN
RT @bradloncar: Oh man.... $AZN really snuck this in on one tiny slide. MYSTIC PFS NOT met. Horrible communications. https://t.co/GL1tqzyzgm
RT @adamfeuerstein: Good morning! (Not for $AZN, with MYSTIC...) https://t.co/Ulc5bQoSpN
RT @bradloncar: Oh man.... $AZN really snuck this in on one tiny slide. MYSTIC PFS NOT met. Horrible communications. https://t.co/GL1tqzyzgm
So while ppl seem to be convinved they should have sold the company at 55 GBP per share $AZN was trading at that level just a few days ago.
AstraZeneca, Merck & Co. enter cancer drug development deal focused on PARP inhibitor Lynparza https://t.co/OboGjxlPrB $AZN $MRK
RT @DailyStockPlays: Large Put Buyers https://t.co/7qkB0qA8hW $ $AZN $ANF $TSCO $LOW $S $GPS $WT $COST $AAL $ $WLL $AAT $CLF $ABBV $AAOI
Large Put Buyers https://t.co/7qkB0qA8hW $ $AZN $ANF $TSCO $LOW $S $GPS $WT $COST $AAL $ $WLL $AAT $CLF $ABBV $AAOI
$AZN: AstraZeneca beats by $0.05, reports revs in-line; reaffirms FY17 guidance https://t.co/xzjq5KW6ZN
RT @bradloncar: Oh man.... $AZN really snuck this in on one tiny slide. MYSTIC PFS NOT met. Horrible communications. https://t.co/GL1tqzyzgm
@sciencescanner I don't even see why a new bid should be lower. 55 GBP per share would be a "standard" premium to c… https://t.co/dAn1VIYCcR
@adamfeuerstein $AZN. MYSTIC A washout.
$AZN monsterstöd-zon ur mkt stort perspektiv https://t.co/0cj7qKPjZA
RT @eirik_nordgaard: Here are this week's top 25 #VPI stocks
$MYL $IBM $GS $DOW $BBY $MMM $AZN $RTN $PYPL $SIRI $MXIM $XLNX $AEO $SBUX
h…
$AZN:
AstraZeneca (AZN) Shares Plunge After MYSTIC Trial Did Not Meet …:
https://t.co/heWXPzryi3
RT @JohnCendpts: I'll keep updating this story through the wee hours of the night. Media call at 4 am ET
$AZN
https://t.co/RopgTQ68k5
AstraZeneca says Phase III MYSTIC trial did not meet primary endpoint $AZN https://t.co/MsorboXQRh
$AZN. MYSTIC Trial fails to meet PFS endpoint for either mono therapy or combo vs. SOC in first line NSCLC. I/O world getting confusing.
Bought 60 $AZN ordinary shares at 43 GBP, now 320 ADRs <-> 160 ord shares. #vssporte https://t.co/OC4po3gw8R
@bradloncar @biotechinvstr @JacobPlieth Only drug Lynparza caliber can bring $1.6B upfront + $6.9B milestone. The o… https://t.co/4EUCpjvNNf
RT @JohnCendpts: Playing for BIG stakes:
$AZN -15%
$MRK +4%
$BMY -6%
https://t.co/RopgTQ68k5
Överväger lite spekulativa calls i $AZN https://t.co/eVolAQHgHU
AstraZeneca beats by $0.05, misses on revenue https://t.co/ah6Rxh4HqP $AZN
AstraZeneca beats by $0.05, misses on revenue https://t.co/v5M96c1tzC $AZN
RT @JohnCendpts: Playing for BIG stakes:
$AZN -15%
$MRK +4%
$BMY -6%
https://t.co/RopgTQ68k5
RT @biotechinvstr: @jq1234t @JacobPlieth @bradloncar Selling the family silver is one thing, this was probably the crown jewel though that…
Imorgon lämnar $SECU rapport, de väntas öka jmf Q1 men lär knappast slå vollan i $AZN ❗️ https://t.co/hUEOU7BG8a
RT @JacobPlieth: Retweeting this for the benefit of those trying to unravel today's MYSTIC fail $AZN https://t.co/nirtgOBE4n
RT @JohnCendpts: AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails in first-line lung cancer
$AZN $MRK
https://t.co/Ropg…
@jq1234t @JacobPlieth @bradloncar Selling the family silver is one thing, this was probably the crown jewel though… https://t.co/RwvX2eYVm3